FBC published a study in the Canadian Journal of Ophthalmology about the physical, emotional and practical challenges that individuals with an inherited retinal disease (IRD) face in Canada.
The study was based on an online survey that asked questions about self-reported vision, genetic testing, health care experiences and disease impact on daily life. The survey was developed by FBC and data was analysed by Dr. Cynthia Qian and Imaan Kherani.
Survey respondents identified having 1 of more than 14 IRDs, with 72% specifying retinitis pigmentosa. 68% reported being legally blind, and more than 85% self-reported moderate to low vision or worse. IRDs impacted daily functioning, with 53% of respondents indicating that their eye disease affected their employment or education. Psychological challenges were evident, with more than 70% worried about coping with daily life, and more than 60% indicating fear and stress. Interviews with individual respondents identified feelings of hopelessness around finding suitable work, loss of independence, and challenges with social interaction with 65% reporting a negative impact on family life. Notably, many had not accessed social support services because of a lack of perceived need, awareness, or availability.
This study was based on responses from over 400 of our community members and we thank all who participated for generously sharing their experience with us and the wider medical and scientific community. This information collected provides a deeper perspective and understanding into what it means to live with a rare and progressive eye disease. It will be a powerful tool as we engage with government, health, and regulatory bodies to improve care and treatments for Canadians living with an IRD.
OGS Encourages Donations to “Light Up Their Eyes This Holiday Season”
To raise awareness of its global impact and encourage fundraising through the end of the year, Optometry Giving Sight (OGS) has kicked off its “Light Up Their Eyes This Holiday Season” campaign. The appeal features stories of how the organization—through the generosity of individual and corporate donors—has provided the gift of sight to people around the world.
Throughout the coming weeks, the campaign will highlight a variety of real-life cases, including those of children in Zambia and Haiti who are better able to learn in school after support from OGS enabled them to be fit with their first pairs of glasses. Another tells the story of a health care professional in India who now incorporates education about primary eye care into her work with her community thanks to OGS-funded training.
“We are so proud of—and grateful for—the progress we’ve made in our mission to end preventable blindness and vision impairment by creating long-term sustainable solutions where they are needed most. But there is always more work to be done, and we can only do it with the help of donors. Every dollar counts,” said Lois Schoenbrun, CAE (Ret.), FAAO, OGS Executive Director, North America. “We hope that by showcasing the personal stories of those whose lives have been changed as a result of our support, people will be inspired to give during the holidays to this important and worthy cause.”
With the support of the ophthalmic industry, optometrists, patients, and other donors, Optometry Giving Sight funds programs to develop sustainable infrastructure, train local eye care professionals, and deliver desperately needed vision care in underserved communities both at home and around the globe.
Click HERE for the full press release.
Glamourama Vol.2: A Love Story
Etnia Barcelona presents eight new acetate models of prescription glasses and five new sunglasses for its Vintage collection. Metal temples designed with Art Deco motifs and classical Vintage trim with dots of colour and gilded pins which differ from model to model to add a touch of sophistication to the collection.
Featured model: Long Island
Distributed by: www.etniabarcelona.com
Brunello Cucinelli and EssilorLuxottica, Together for the Next Ten Years
Brunello Cucinelli Casa di Moda and EssilorLuxottica signed, at Casa Cucinelli in Milan, an exclusive ten-year license agreement for the design, manufacture and distribution of eyewear under the “Brunello Cucinelli” brand.
The new agreement will come into effect on January 1, 2023 and run until December 31, 2032. The first collection will be introduced to the market in the first quarter of 2024. This agreement represents an extension of the ongoing collaboration between the two companies started in 2021, which included the launch of a capsule collection signed by Brunello Cucinelli and Oliver Peoples.
Brunello Cucinelli, Executive Chairman and Creative Director of the Casa di Moda said: “The choice we met with the highly esteemed EssilorLuxottica is much more than an agreement. It is a token of mutual affection and respect between two realities that are inspired by a passion for beauty and for things done well.”
Francesco Milleri, Chairman and CEO of EssilorLuxottica commented: “We are thrilled to continue our journey with Brunello Cucinelli, a luxury lifestyle brand that represents the glamour of contemporary Italian style. Through our new branded eyewear collections, we will continue to deliver beautifully designed and crafted eyewear that embody the best of Brunello Cucinelli style for the consumers around the world.”
Click HERE for the full press release.
Alcon Completes Acquisition of Aerie Pharmaceuticals
Alcon announced that it has completed its acquisition of Aerie Pharmaceuticals (Aerie).
Through the transaction, Alcon has added the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye disease. Alcon has also acquired a pipeline of ophthalmic pharmaceutical product candidates with the opportunity to leverage Aerie’s existing research and development capabilities.
“As we welcome the Aerie team to Alcon, we look forward to leveraging our expanding commercial footprint and expertise to bring Rocklatan® and Rhopressa® to even more customers and their patients,” said David Endicott, CEO of Alcon.
The transaction complements Alcon’s expansion into the ophthalmic pharmaceutical space, including acquisitions of the exclusive U.S. commercialization rights for Simbrinza® from Novartis in April 2021 and Eysuvis® and Inveltys® from Kala Pharmaceuticals, Inc. in May 2022.
Alcon intends to fully integrate Aerie into its business. As previously disclosed, the Company has used debt to fund the transaction for a total purchase consideration of approximately $930 million.
Click HERE for the full press release.

